



Group Assisted Purification (GAP) Chemistry provides unique advantages for production of synthetic peptides.

GAP Peptides, LLC (GAPP) is pleased to announce the United States Patent and Trademark Office (USPTO) has issued a new Patent (Patent No. 10,947,267 B2) to Texas Tech University System (TTUS) for the **System and Method for Solution Phase Gap Peptide Synthesis**. The technology was co-invented by GAPP's Chief Scientific Officer, Dr. Cole Seifert and was exclusively licensed from TTUS by GAP Peptides, LLC in 2017.

This patent is the first issued for the application of Group Assisted Purification (GAP) Chemistry to the synthesis of peptides. GAP Chemistry is defined as *a chemistry for organic synthesis that avoids traditional purification methods such as chromatography and/or recrystallization by purposefully introducing a well-functionalized group in the starting material or in the newly generated product.*

The application of GAP Chemistry to solution-phase peptide synthesis, including the development of a new benzyl-type GAP protecting group, and related uses thereto, is significant in addressing the challenges of scaleup, process efficiency and cost control found in traditional synthesis methods. **Group Assisted Purification Peptide Synthesis (GAP-PS)** requires no special equipment and utilizes standard chemistry to deliver economical, efficient production of high crude-purity peptides in high yield.

It is rewarding that the USPTO is recognizing the work of Drs. Guigen Li and Cole Seifert, inventors of the approach. It's also exciting for the peptide industry overall, which has seen a surge in the number of therapeutics in clinical trial and a growing market demand for peptide-based products that fight diseases and improve the quality of life.

About GAP Peptides, LLC

GAP Peptides, LLC is a peptide synthesis innovator focused on solving the inefficiencies found in traditional peptide synthesis. In large-scale production of peptides, costs, scalability, process efficiency and sustainability are critical issues. GAP-PS is a novel approach to peptide synthesis that delivers a highly efficient and economical solution for companies developing and commercializing peptides used in cosmetics, pharmaceuticals, R&D, diagnostic imaging, and many other related applications. The Company currently has 4 patent families in process globally with additional technology developments underway.

GAPP's business model enables use of the IP via sublicense to companies seeking sustainable, economical, scalable green chemistry for large scale peptide production. For additional company information, please visit www.GAPPeptides.com